CB6F1-rasH2 Mouse: Overview of Available Data

Abstract

This article presents data from short-term carcinogenicity studies of compounds tested in the CB6F1-rasH2 transgenic mouse as part of the International Life Sciences Institutes' (ILSI) Health and Environmental Sciences' (HESI) Alternative to Carcinogenicity Testing (ACT) project. Additionally, data from other studies that were not conducted as part of the ILSI program, but used comparable or slightly modifi ed protocols, are included here. A signifi cant number (3 of 4) of the genotoxic carcinogens tested were positive in the rasH2 mouse; the other compound was equivocally positive. The positive control, N-Methyl-N-nitrosurea (MNU), gave reproducible responses across all participating laboratories with tumors noted at multiple sites in the animal. The immunosuppressive human carcinogen, Cyclosporin A, was equivocal. Two hormones that are human tumorigens, Diethylstilbestrol and 17β-Estradiol, gave positive and negative results, respectively. Of the twelve additional compounds tested that are classifi ed as non-genotoxic rodent carcinogens and putative human non-carcinogens, only the two peroxisome proliferators (clofi brate and diethylhexylphthalate(DEHP)) produced a positive response (liver effects). The three non-genotoxic non-carcinogens that were tested also gave negative responses in the rasH2 model. This result provides confi dence that the model is likely to have a low false-positive rate.

Keywords

cHa ras proto-oncogene transgenic mouse bioassay short-term 26-Weeks alternatives carcinogenicity testing.

References

Ando K.

Saitoh A.

Hino O.

Takahashi R.

Kimura M.

Katsuki M.

(1992). Chemically induced forestomach papillomas in transgenic mice carry mutant human c-ha-ras transgenes. Cancer Res52(4): 978—982.

Doi ST

Kimura M.

Katsuki M.

(1994). Site-specifi c mutation of the human c-Ha-ras transgene induced by dimethylbenzanthracene causes tissuespecifi c tumors in mice. Jpn J Cancer Res85(8): 801—807.

Gulezian D.

Jacobson-Ram D.

McCullough CB

Olson H.

Recio L.

Robinson D.

Storer R.

Tennant R.

Ward JM

Neumann DA

(2000). Use of transgenic animals for carcinogenicity testing: considerations and implications for risk assessment. Toxicol Pathol28(3): 482—499.

Hayashi S.

Mori I.

Nonoyama T.

Mitsumori K.

(1998). Point mutations of the c-H-ras gene in spontaneous liver tumors of transgenic mice carrying the human c-H-ras gene. Toxicol Pathol26(4): 556—561.

Katsutani N.

Sekido T.

Aoki T.

Sagami F.

(2000). Hepatic drug metabolizing enzymes induced by chlorofi brate in rasH2 mice . Toxicol Lett115(3): 223—229.

KobayashiK.

SanoF.

MutaiM.

SugimotoJ.

(2000). Glomerulonephritiswith fi brillary deposition in a transgenic mouse carrying the human prototype c-Ha-ras (rasH2 mouse) . Toxicol Pathol28(2): 359—362.

Koujitani T.

Yasuhara K.

Usui T.

Nomura T.

Onodera H.

Takagi H.

Hirose M.

Mitsumori K.

(2000). Lack of susceptibility of transgenic mice carrying the human c-Ha-ras proto-oncogene (rasH2 mice) to phenolphthalein in a 6-month carcinogenicity study. Cancer Lett152(2): 211—216.

Maronpot RR

Mitsumori K.

Mann P.

Takaoka M.

Yamamoto S.

Usui T.

Okamiya H.

Nishikawa S, Nomura

(2000). Interlaboratory comparison of the CB6F1-Tg rasH2 rapid carcinogenicity testing model. Toxicology146(2—3): 149—159.

Mirkes PE

Fantel AG

Greenaway JC

Shepard TH

(1981). Teratogenicity of cyclophosphamide metabolites: phosphoramide mustard, acrolein, and 4-ketocyclophosphamidein rat embryos cultured in vitro. Toxicol Appl Pharmacol58: 322—330.

10.

Mitsumori K.

Yasuhara K.

Mori I.

Hayashi S.

Shimo T.

Onodera H.

Nomura T.

Hayashi Y.

(1998). Pulmonary fi brosis caused by N-methyl-N-nitrosourethaneinhibits lunch tumorigenesis by urethane in transgenic mice carrying the human prototype c-Ha-ras gene . Cancer Lett129(2): 181—190.

11.

Mitsumori K.

Koizumi H.

Nomura T.

Yamamoto S.

(1998). Pathological features of spontaneous and induced tumors in transgenic mice carrying a human prototype c-Ha-ras gene used for six-month carcinogenicity studies. ToxicolPathol26(4): 520—531.

12.

Mori I.

Yasuhara K.

Hayashi SM

Nonoyama T.

Nomura T.

Mitsumori K.

(2000). Carcinogen dose-dependent variation in the transgene mutation spectrum in urethane-induced lung tumors in transgenic mice carrying the human prototype c-Ha-ras gene. Cancer Lett153(1—2): 199—209.

13.

Storer RD

(2000). Current status and use of short/medium term models for carcinogenicity testing of pharmaceuticals—scientifi c perspective . Toxicol Lett112-113(2): 557—566.

14.

Takegawa K.

Mitsumori K.

Yasuhara K.

Moriyasu M.

Sakamori M.

Onodera H.

Hirose M.

Nomura T.

(2000). A mechanistic study of ovarian carcinogenesis induced by nitrofurazone using rasH2 mice. Toxicol Pathol28(5): 649—655.

15.

Tsunematsu S.

Saito H.

Kagawa T.

Morizane T.

Hata J.

Nakamura T.

Ishii H.

Tsuchiya M.

Nomura T.

Katsuki M.

(1994). Hepatic tumors induced by carbon tetrachloride in transgenic mice carrying a human c-H-ras proto-oncogene without mutations. Int J Cancer59(4): 554—559.

16.

Tsunematsu S.

Saito H.

Sato R.

Morizane T.

Ishii H.

(1997). Role of H-ras gene in chronic liver damage in mice by using transgenic mice carrying a human c-H-ras proto-oncogene without mutations. Biochem Mol Biol Int42(2): 371—379.

17.

Tsunematsu S.

Saito H.

Tada S.

Ebinuma H.

Tsuchiya M.

Kumagai N.

Morizane T.

Nomura T.

Ishii H.

(1997). Susceptibility of experimental autoimmune hepatitis in transgenic mice overexpressing the c-H-ras gene. J Gastroenterol Hepatol12(4): 319—324.

18.

Umemura T.

Kodama Y.

Hioki K.

Inoue T.

Nomura T.

Kurokawa Y.

(1999). Susceptibility to urethane carcinogenesis of transgenic mice carrying a human prototype c-Ha-ras gene (rasH2 mice) and its modifi cation by butyl-hydroxytoluene. Cancer Lett145(1—2): 101—106.

19.

Yamamoto S.

Mitsumori K.

Kodama Y.

Matsunuma N.

Manabe S.

Okamiya H.

Suzuki H.

Fukuda T.

Sakamaki Y.

Sunaga M.

Nomura G.

Hioki K.

Wakana S.

Nomura T.

Hayashi Y.

(1996). Rapid induction of more malignant tumors by various genotoxic carcinogens in transgenic mice harboring a human prototype c-Ha-ras gene than in control non-transgenic mice. Carcinogenesis17(11): 2455—2461.

20.

Yamamoto S.

Urano K.

Nomura T.

(1998). Validation of transgenic mice harboring the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing. Toxicol Lett102-103(1—2): 473—478.

21.

Yamamoto S.

Urano K.

Koizumi H.

Wakana S.

Hioki K.

Mitsumori K.

Kurokawa Y.

Hayashi Y.

Nomura T.

(1998). Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing. Environ Health Perspect106 Suppl 1(4): 57—69.